Latham & Watkins Advises Cheplapharm on €1.2 Billion Term Loan B

Latham & Watkins LLP has advised Cheplapharm Arzneimittel GmbH (Cheplapharm), a European leader in well-established medicines, on its €1.2 billion seven-year term loan B. The proceeds will be used to partially refinance Cheplapharm’s existing €1.28 billion term loan B due 2029.

The refinancing follows Cheplapharm’s recently announced strategic partnership with Sanofi. Earlier this year, Cheplapharm also issued €950 million 6.75% senior secured notes due 2032. Latham & Watkins advised Cheplapharm on both of these transactions.

The Latham team was led by Frankfurt Capital Markets partner Jan Penselin, Frankfurt Banking & Private Credit partner Alexandra Hagelüken, and counsel Cora Grannemann, with associate Yan Ma. Advice was also provided on capital markets matters by associates Peter Neuböck and Tobias Müller.